Literature DB >> 17222367

[Correlation of p38 mitogen-activated protein kinase signal transduction pathway to uPA expression in breast cancer].

Yan-Chun Han1, Xian-Xu Zeng, Rui Wang, Yan Zhao, Bai-Lin Li, Min Song.   

Abstract

BACKGROUND &
OBJECTIVE: p38 mitogen-activated protein kinase (p38MAPK) signal transduction pathway regulates the expression of various metastasis-related genes. Urokinase-type plasminogen activator (uPA) plays an important role in cancer invasion and metastasis. This study was to explore the correlation of p38MAPK signal transduction pathway to uPA expression in breast cancer.
METHODS: SP immunohistochemistry was used to test the expression of p-p38, p-Akt, p-Erk, and uPA in 60 specimens of breast cancer. Western blot was used to detect the protein levels of p-p38 and uPA in breast cancer MDA-MB-231 and MCF-7 cells and the protein level of uPA in MDA-MB-231 cells after blocking p38MAPK signal transduction pathway by SB203580, a specific inhibitor of p38MAPK. The correlations of p-p38, p-Akt, p-Erk, and uPA expression to the clinicopathologic characteristics of breast cancer, and the correlations of p-p38, p-Akt, and p-Erk expression to uPA expression were analyzed. The mechanism of p38MAPK signal transduction pathway regulating the protein expression of uPA in breast cancer cells was investigated. The correlation of p-p38 and uPA expression to prognosis of breast cancer was analyzed.
RESULTS: The positive rates of p-p38, p-Akt, p-Erk, and uPA proteins in breast cancer tissues were 56.7%, 95.0%, 93.3%, and 60.0%, respectively. The expression of p-p38 was positively correlated to the expression of uPA (r=0.316, P<0.05), while the expression of p-Akt and p-Erk was not related to uPA expression. The expression of p-p38 and uPA was correlated to lymph node metastasis and TNM stage (P<0.05), but not to patients' age and tumor size (P>0.05). The expression of p-Akt and p-Erk were correlated to lymph node metastasis (P<0.05), but not to TNM stage, patients' age, and tumor size (P>0.05). The protein levels of p-p38 and uPA in MDA-MB-231 cells were higher than that in MCF-7 cells. SB203580 concentration-dependently inhibited p38MAPK pathway and induced uPA protein expression. The expression of p-p38 and uPA was negatively correlated to prognosis of breast cancer (log-rank=4.98, 5.40, P=0.026, 0.020).
CONCLUSIONS: p38MAPK signal transduction pathway might improve breast cancer progression by up-regulating uPA expression, and might be an important route in invasion and metastasis of breast cancer. p-p38 and uPA might help to evaluate prognosis of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17222367

Source DB:  PubMed          Journal:  Ai Zheng


  6 in total

Review 1.  A review: hippo signaling pathway promotes tumor invasion and metastasis by regulating target gene expression.

Authors:  Hong-Li Li; Qian-Yu Li; Min-Jie Jin; Chao-Fan Lu; Zhao-Yang Mu; Wei-Yi Xu; Jian Song; Yan Zhang; Sai-Yang Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2021-04-17       Impact factor: 4.553

Review 2.  Role of p38 MAP Kinase Signal Transduction in Solid Tumors.

Authors:  Hari K Koul; Mantu Pal; Sweaty Koul
Journal:  Genes Cancer       Date:  2013-09

3.  Weighted change-point method for detecting differential gene expression in breast cancer microarray data.

Authors:  Yao Wang; Guang Sun; Zhaohua Ji; Chong Xing; Yanchun Liang
Journal:  PLoS One       Date:  2012-01-20       Impact factor: 3.240

4.  Phosphorylated-p38 mitogen-activated protein kinase expression is associated with clinical factors in invasive breast cancer.

Authors:  Bin Wang; Huayong Jiang; Ning Ma; Yajie Wang
Journal:  Springerplus       Date:  2016-06-30

5.  Inhibitors of PI3K/ERK1/2/p38 MAPK Show Preferential Activity Against Endocrine-Resistant Breast Cancer Cells.

Authors:  Maitham A Khajah; Princy M Mathew; Yunus A Luqmani
Journal:  Oncol Res       Date:  2017-03-08       Impact factor: 5.574

6.  Inhibitory Effects of PC-SPESII Herbal Extract on Human Breast Cancer Metastasis.

Authors:  Xiu-Feng Wang; Jia Du; Tian-Ling Zhang; Qian-Mei Zhou; Yi-Yu Lu; Hui Zhang; Shi-Bing Su
Journal:  Evid Based Complement Alternat Med       Date:  2013-06-25       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.